Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bladder cancer.
de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN. de Braud F, et al. Among authors: maffezzini m. Crit Rev Oncol Hematol. 2002 Jan;41(1):89-106. doi: 10.1016/s1040-8428(01)00128-7. Crit Rev Oncol Hematol. 2002. PMID: 11796234 Review.
Bladder cancer.
Maffezzini M, Audisio R, Pavone-Macaluso M, Hall RR. Maffezzini M, et al. Crit Rev Oncol Hematol. 1998 Feb;27(2):151-3. doi: 10.1016/s1040-8428(97)10026-9. Crit Rev Oncol Hematol. 1998. PMID: 9571320 Review. No abstract available.
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R. Necchi A, et al. Among authors: maffezzini m. Clin Genitourin Cancer. 2014 Jun;12(3):203-209.e1. doi: 10.1016/j.clgc.2013.11.022. Epub 2013 Nov 21. Clin Genitourin Cancer. 2014. PMID: 24394493
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy.
Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, Nicolai N, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Maffezzini M, Gianni AM, De Braud F, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Necchi A, et al. Among authors: maffezzini m. Clin Genitourin Cancer. 2015 Apr;13(2):171-7.e1. doi: 10.1016/j.clgc.2014.08.002. Epub 2014 Aug 8. Clin Genitourin Cancer. 2015. PMID: 25193365
Breast cancer metastases of the urinary bladder.
Rigatti P, Broglia L, Montorsi F, Maffezzini M, Sironi M, Radice F, Abelli P, Pace M, Diamantini S, Veronesi AM, et al. Rigatti P, et al. Among authors: maffezzini m. Int J Tissue React. 1991;13(3):159-63. Int J Tissue React. 1991. PMID: 1660044
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Maffezzini M, Campodonico F, Canepa G, Manuputty EE, Tamagno S, Puntoni M. Maffezzini M, et al. Cancer Chemother Pharmacol. 2014 May;73(5):925-30. doi: 10.1007/s00280-014-2423-y. Epub 2014 Mar 1. Cancer Chemother Pharmacol. 2014. PMID: 24585046
Estimates of prostate cancer burden in Italy.
Capocaccia R, Foschi R, Zucchetto A, Valdagni R, Nicolai N, Maffezzini M, Gatta G. Capocaccia R, et al. Among authors: maffezzini m. Cancer Epidemiol. 2016 Feb;40:166-72. doi: 10.1016/j.canep.2015.12.004. Epub 2015 Dec 29. Cancer Epidemiol. 2016. PMID: 26771313
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. Necchi A, et al. Among authors: maffezzini m. Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26. Invest New Drugs. 2014. PMID: 24566706 Clinical Trial.
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A. Raggi D, et al. Among authors: maffezzini m. Urol Oncol. 2015 Jul;33(7):332.e19-24. doi: 10.1016/j.urolonc.2015.04.008. Epub 2015 May 16. Urol Oncol. 2015. PMID: 25985712
122 results